Enhanced antimyeloma cytotoxicity by the combination of arsenic trioxide and bortezomib is further potentiated by p38 MAPK inhibition

Leukemia Research

Volumn 34, Issue 1, 2010, Pages 85-92

  Wen, Jianguo ^a   Feng, Yongdong ^a   Huang, Wanting ^b   Chen, Haiyun ^c   Liao, Bing ^a   Rice, Lawrence ^a   Preti, Hector A ^a   Kamble, Rammurti T ^d   Zu, Youli ^a,e   Ballon, Douglas J ^e   Chang, Chung Che ^a,e  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c NEW YORK METHODIST HOSPITAL   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

ATO; Bortezomib; Myeloma; p38 MAPK

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ARSENIC TRIOXIDE; BIM PROTEIN; BORTEZOMIB; HEAT SHOCK PROTEIN 27; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN BCL 2; PROTEIN P27; PROTEIN P53; STAT3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; SYNDECAN 1;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; MYELOMA CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; STROMA CELL; TUMOR CELL; UPREGULATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARSENICALS; BORONIC ACIDS; DRUG SYNERGISM; ENZYME ACTIVATION; HSP27 HEAT-SHOCK PROTEINS; HUMANS; MULTIPLE MYELOMA; OXIDES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRAZINES; STAT3 TRANSCRIPTION FACTOR;

EID: 73249129928     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.05.024     Document Type: Article

References (49)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics, 2007. CA Cancer J Clin 57 (2007) 43-66
2. Hideshima T., Podar K., Chauhan D., et al. p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. Oncogene 23 (2004) 8766-877676
3. Wen J., Cheng H.Y., Feng Y., et al. P38 MAPK inhibition enhancing ATO-induced cytotoxicity against multiple myeloma cells. Br J Haematol 140 (2008) 169-18080
4. Cavo M. Proteasome inhibitor bortezomib for the treatment of multiple myeloma. Leukemia 20 (2006) 1341-135252
5. Nencioni A., Grunebach F., Patrone F., Ballestrero A., and Brossart P. Proteasome inhibitors: antitumor effects and beyond. Leukemia 21 (2007) 30-366
6. Richardson P.G., Barlogie B., Berenson J., et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348 (2003) 2609-261717
7. Munshi N.C., Tricot G., Desikan R., et al. Clinical activity of arsenic trioxide for the treatment of multiple myeloma. Leukemia 16 (2002) 1835-18377
8. Berenson J.R., Matous J., Swift R.A., Mapes R., Morrison B., and Yeh H.S. A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma. Clin Cancer Res 13 (2007) 1762-17688
9. Campbell R.A., Sanchez E., Steinberg J.A., et al. Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid. Br J Haematol 138 (2007) 467-47878
10. Stromberg T., Ekman S., Girnita L., et al. IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells. Blood 107 (2006) 669-67878
11. Cuenda A., Rouse J., Doza Y.N., et al. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett 364 (1995) 229-23333
12. Birkenkamp K.U., Tuyt L.M., Lummen C., Wierenga A.T., Kruijer W., and Vellenga E. The p38 MAP kinase inhibitor SB203580 enhances nuclear factor-kappa B transcriptional activity by a non-specific effect upon the ERK pathway. Br J Pharmacol 131 (2000) 99-107
13. Piantelli M., Tatone D., Castrilli G., et al. Quercetin and tamoxifen sensitize human melanoma cells to hyperthermia. Melanoma Res 11 (2001) 469-47676
14. Calviello G., Di Nicuolo F., Serini S., et al. Docosahexaenoic acid enhances the susceptibility of human colorectal cancer cells to 5-fluorouracil. Cancer Chemother Pharmacol 55 (2005) 12-20
15. Hideshima T., Mitsiades C., Tonon G., Richardson P.G., and Anderson K.C. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 7 (2007) 585-59898
16. 3) in the treatment of acute promyelocytic leukemia (APL). II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89 (1997) 3354-336060
17. Orlowski R.Z., Stinchcombe T.E., Mitchell B.S., et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 20 (2002) 4420-44277
18. Olivier S., Close P., Castermans E., et al. Raloxifene-induced myeloma cell apoptosis: a study of nuclear factor-kappaB inhibition and gene expression signature. Mol Pharmacol 69 (2006) 1615-162323
19. Bornhauser B.C., Bonapace L., Lindholm D., et al. Low-dose arsenic trioxide sensitizes glucocorticoid-resistant acute lymphoblastic leukemia cells to dexamethasone via an Akt-dependent pathway. Blood 110 (2007) 2084-209191
20. Yan H., Wang Y.C., Li D., et al. Arsenic trioxide and proteasome inhibitor bortezomib synergistically induce apoptosis in leukemic cells: the role of protein kinase Cdelta. Leukemia 21 (2007) 1488-149595
21. Chauhan D., Li G., Hideshima T., et al. JNK-dependent release of mitochondrial protein, Smac, during apoptosis in multiple myeloma (MM) cells. J Biol Chem 278 (2003) 17593-175966
22. Hideshima T., Mitsiades C., Akiyama M., et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 101 (2003) 1530-15344
23. Davis R.J. Signal transduction by the JNK group of MAP kinases. Cell 103 (2000) 239-25252
24. Ikeda F., Matsubara T., Tsurukai T., Hata K., Nishimura R., and Yoneda T. JNK/c-Jun signaling mediates an anti-apoptotic effect of RANKL in osteoclasts. J Bone Miner Res 23 (2008) 907-91414
25. Giafis N., Katsoulidis E., Sassano A., et al. Role of the p38 mitogen-activated protein kinase pathway in the generation of arsenic trioxide-dependent cellular responses. Cancer Res 66 (2006) 6763-677171
26. Darnell Jr. J.E. Transcription factors as targets for cancer therapy. Nat Rev Cancer 2 (2002) 740-7499
27. Gao S.P., and Bromberg J.F. Touched and moved by STAT3. Sci STKE (2006) pe30
28. Pathak A.K., Bhutani M., Nair A.S., et al. Ursolic acid inhibits STAT3 activation pathway leading to suppression of proliferation and chemosensitization of human multiple myeloma cells. Mol Cancer Res 5 (2007) 943-95555
29. Mortenson M.M., Schlieman M.G., Virudachalam S., et al. Reduction in BCL-2 levels by 26S proteasome inhibition with bortezomib is associated with induction of apoptosis in small cell lung cancer. Lung Cancer 49 (2005) 163-17070
30. Fahy B.N., Schlieman M.G., Mortenson M.M., Virudachalam S., and Bold R.J. Targeting BCL-2 overexpression in various human malignancies through NF-kappaB inhibition by the proteasome inhibitor bortezomib. Cancer Chemother Pharmacol 56 (2005) 46-54
31. Fennell D.A., Chacko A., and Mutti L. BCL-2 family regulation by the 20S proteasome inhibitor bortezomib. Oncogene 27 (2008) 1189-119797
32. Lunghi P., Giuliani N., and Mazzera L. Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways. Blood (2008)
33. Harris C.A., and Johnson Jr. E.M. BH3-only Bcl-2 family members are coordinately regulated by the JNK pathway and require Bax to induce apoptosis in neurons. J Biol Chem 276 (2001) 37754-3776060
34. Yang J., Liu X., Bhalla K., et al. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 275 (1997) 1129-113232
35. Craig C., Wersto R., Kim M., et al. A recombinant adenovirus expressing p27Kip1 induces cell cycle arrest and loss of cyclin-Cdk activity in human breast cancer cells. Oncogene 14 (1997) 2283-22899
36. Shibata M.A., Yoshidome K., Shibata E., Jorcyk C.L., and Green J.E. Suppression of mammary carcinoma growth in vitro and in vivo by inducible expression of the Cdk inhibitor p21. Cancer Gene Ther 8 (2001) 23-35
37. Lin Q., Lai R., Chirieac L.R., et al. Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines: inhibition of JAK3/STAT3 signaling induces apoptosis and cell cycle arrest of colon carcinoma cells. Am J Pathol 167 (2005) 969-98080
38. Xiao H., Zhang Q., Lin Y., Reddy B.S., and Yang C.S. Combination of atorvastatin and celecoxib synergistically induces cell cycle arrest and apoptosis in colon cancer cells. Int J Cancer 122 (2008) 2115-212424
39. Navas T.A., Nguyen A.N., Hideshima T., et al. Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo. Leukemia 20 (2006) 1017-102727
40. Concannon C.G., Gorman A.M., and Samali A. On the role of Hsp27 in regulating apoptosis. Apoptosis 8 (2003) 61-70
41. Creagh E.M., Sheehan D., and Cotter T.G. Heat shock proteins-modulators of apoptosis in tumour cells. Leukemia 14 (2000) 1161-117373
42. Guay J., Lambert H., Gingras-Breton G., Lavoie J.N., Huot J., and Landry J. Regulation of actin filament dynamics by p38 map kinase-mediated phosphorylation of heat shock protein 27. J Cell Sci 110 Pt 3 (1997) 357-36868
43. Huot J., Houle F., Marceau F., and Landry J. Oxidative stress-induced actin reorganization mediated by the p38 mitogen-activated protein kinase/heat shock protein 27 pathway in vascular endothelial cells. Circ Res 80 (1997) 383-39292
44. Landry J., and Huot J. Modulation of actin dynamics during stress and physiological stimulation by a signaling pathway involving p38 MAP kinase and heat-shock protein 27. Biochem Cell Biol 73 (1995) 703-7077
45. Mitsiades N., Mitsiades C.S., Poulaki V., et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA 99 (2002) 14374-143799
46. New L., Jiang Y., Zhao M., et al. PRAK, a novel protein kinase regulated by the p38 MAP kinase. EMBO J 17 (1998) 3372-338484
47. Xanthoudakis S., and Nicholson D.W. Heat-shock proteins as death determinants. Nat Cell Biol 2 (2000) E163-E165
48. Zaarur N., Gabai V.L., Porco Jr. J.A., Calderwood S., and Sherman M.Y. Targeting heat shock response to sensitize cancer cells to proteasome and Hsp90 inhibitors. Cancer Res 66 (2006) 1783-179191
49. Dominguez C., Powers D.A., and Tamayo N. p38 MAP kinase inhibitors: many are made, but few are chosen. Curr Opin Drug Discov Devel 8 (2005) 421-43030